Mereo BioPharma Group plc: Our Partner Ultragenyx Announces First Patient Dosed in Pivotal Phase 2/3 Clinical Study of Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta - MoneyController (ID 747982)
Scopus BioPharma Inc. (SCPS) Stock Price, Quote, News & History | Nasdaq